Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Clinical Research Generic Drugs Market Trends Oncology Pricing Strategies GLP-1 Drugs Market Competition Obesity Treatment Alzheimer's Disease Regulatory Approval Market Dynamics Obesity Treatments Manufacturing Monoclonal Antibodies Oncology Drugs Cancer Treatment Immunology GLP-1 Treatments Injectable Medications Preventive Medicine Metabolic Diseases Weight Loss Medications Pipeline COVID-19 Vaccines Rare Diseases Antibiotics Cancer Treatments Duchenne Muscular Dystrophy Weight-Loss Drugs Injectable Treatments Generic Medications GLP-1 Agonists Research and Development Weight Loss Treatments Weight-loss Drugs Diabetes Treatments Obesity Drugs Topical Treatments Oral Medications Eli Lilly Products Eli Lilly Gilead Sciences Production Facilities Innovative Treatments FDA Approvals Acquisitions Diagnostics Small Molecule Inhibitors Alzheimer's Treatments Vaccine Manufacturing AI in Medicine Regulatory Affairs Antiviral Drugs Weight Loss Products Genetic Medicine Targeted Therapies Natural Products Long-acting Medications Approval Process Malaria Treatment Patent Issues Imdelltra Anti-Inflammatory Drugs Neuroscience Dermatology Contract Research AI in Healthcare Neurology Therapeutic Areas Specialty Medicines Peptide Drugs Pricing Policies CRDMO NRTTIs Psychedelic Drugs Legal Issues Inflammatory Conditions Market Impact Experimental Drugs Therapeutics Therapeutic Innovation FDA Approval Process Gene Therapy Incretin and Non-Incretin Analogue Peptides Emergency Treatments Investment Access to Medicines Innovative Medicines FDA Approval Generic Medicines Market Potential Biologics Addiction Medicine Patent Expiration Vaccines NHS Funding Weight Management Access to Medicine

Eli Lilly Picks Huntsville for $6 Billion API Plant to Scale Obesity Pill Production

The project expands U.S. drug-making capacity to support Lilly’s oral GLP-1 pill under priority FDA review.

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

Bristol Myers and J&J Cast as Dividend Plays as Bayer’s FXIa Win Refocuses Pipeline Interest

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Eli Lilly Briefly Hits $1 Trillion, First Drugmaker to Reach the Milestone

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

Novartis Lifts Cancer-Drug Forecasts, Targets 5%–6% Sales Growth Through 2030

aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall